[Form 4] Quest Diagnostics Inc. Insider Trading Activity
The filing reports insider activity by Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics (DGX). On 08/13/2025 he had a disposition of 123 shares of Quest Diagnostics common stock executed under code F at a price of $175.91 per share; the filer states this sale was made solely to cover tax withholding on vested restricted stock units. Following the reported transaction, Kuppusamy beneficially owned 8,338 shares directly, plus 358 shares indirectly via a trust and 1,628 shares held in the 401(k) plan, with the 401(k) amount provided by the plan administrator based on current account balances.
La comunicazione riporta un'operazione insider effettuata da Karthik Kuppusamy, SVP Clinical Solutions presso Quest Diagnostics (DGX). In data 13/08/2025 ha effettuato una cessione di 123 azioni ordinarie di Quest Diagnostics, eseguita con codice F al prezzo di $175,91 per azione; il dichiarante precisa che la vendita 猫 stata fatta esclusivamente per coprire il prelievo fiscale su stock unit gi脿 maturate. Dopo la transazione segnalata, Kuppusamy deteneva 8.338 azioni direttamente, oltre a 358 azioni indirettamente tramite un trust e 1.628 azioni nel piano 401(k), importo fornito dall'amministratore del piano in base ai saldi correnti del conto.
El informe comunica una operaci贸n de insider realizada por Karthik Kuppusamy, SVP de Clinical Solutions en Quest Diagnostics (DGX). El 13/08/2025 tuvo una disposici贸n de 123 acciones ordinarias de Quest Diagnostics ejecutada bajo el c贸digo F a $175.91 por acci贸n; el declarante indica que la venta se realiz贸 煤nicamente para cubrir la retenci贸n fiscal sobre unidades restringidas de acciones ya consolidadas. Tras la operaci贸n reportada, Kuppusamy pose铆a 8.338 acciones en propiedad directa, adem谩s de 358 acciones indirectamente a trav茅s de un fideicomiso y 1.628 acciones en el plan 401(k), cantidad facilitada por el administrador del plan seg煤n los saldos actuales de la cuenta.
鞚� 瓿奠嫓電� Quest Diagnostics(DGX)鞚� SVP, Clinical Solutions鞚� Karthik Kuppusamy鞚� 雮措秬鞛� 瓯半灅毳� 氤搓碃頃╇媹雼�. 2025-08-13鞐� 攴鸽姅 旖旊摐 F搿� 鞁ろ枆霅� Quest Diagnostics 氤错喌欤� 123欤� 觳橂秳鞚� 欤茧嫻 $175.91鞐� 歆勴枆頄堨溂氅�, 鞁犼碃鞚胳潃 鞚� 毵り皝鞚� 鞚措 頇曥爼霅� 鞝滍暅 欤检嫕 雼渼鞚� 靹戈笀 鞗愳矞歆曥垬鞖�鞙茧毵� 鞚措（鞏挫雼り碃 氚濏様鞀惦媹雼�. 氤搓碃霅� 瓯半灅 鞚错泟 Kuppusamy電� 歆侅爲 氤挫湢 8,338欤�鞕赌 鞁犿儊鞚� 韱淀暅 臧勳爲 氤挫湢 358欤�, 攴鸽Μ瓿� 401(k) 頂岆灉鞐� 氤挫湢霅� 1,628欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 401(k) 靾橃箻電� 頂岆灉 甏�毽瀽鞐� 鞚橅暣 順勳灛 瓿勳 鞛旍暋鞚� 旮办鞙茧 鞝滉车霅橃棃鞀惦媹雼�.
Le d茅p么t signale une op茅ration d'initi茅 r茅alis茅e par Karthik Kuppusamy, SVP Clinical Solutions chez Quest Diagnostics (DGX). Le 13/08/2025, il a proc茅d茅 脿 une cession de 123 actions ordinaires de Quest Diagnostics ex茅cut茅e sous le code F au prix de 175,91 $ par action ; le d茅clarant indique que cette vente a 茅t茅 effectu茅e uniquement pour couvrir la retenue fiscale sur des unit茅s d'actions restreintes acquises. Apr猫s la transaction signal茅e, Kuppusamy d茅tenait 8 338 actions en propri茅t茅 directe, plus 358 actions indirectement via une fiducie et 1 628 actions d茅tenues dans le plan 401(k), le montant 401(k) ayant 茅t茅 fourni par l'administrateur du plan sur la base des soldes de comptes actuels.
Die Meldung berichtet 眉ber Insider-Aktivit盲ten von Karthik Kuppusamy, SVP Clinical Solutions bei Quest Diagnostics (DGX). Am 13.08.2025 ver盲u脽erte er unter dem Code F 123 Aktien der Quest Diagnostics-Stammaktien zu einem Preis von $175,91 je Aktie; der Einreicher gibt an, dass der Verkauf ausschlie脽lich zur Deckung der Steuerabz眉ge auf ausge眉bte Restricted Stock Units erfolgt sei. Nach der gemeldeten Transaktion besa脽 Kuppusamy 8.338 Aktien direkt, zus盲tzlich 358 Aktien indirekt 眉ber einen Trust und 1.628 Aktien im 401(k)-Plan, wobei der 401(k)-Betrag vom Planadministrator auf Grundlage der aktuellen Kontost盲nde angegeben wurde.
- Insider retains meaningful direct ownership of 8,338 shares, indicating continued alignment with shareholder interests
- Additional indirect holdings include 358 shares via trust and 1,628 shares in the 401(k) plan, showing ongoing participation in company equity programs
- Disposition of 123 shares was recorded, though the filing states this was solely to satisfy tax withholding obligations
Insights
TL;DR: Small, non-discretionary sale to satisfy tax withholding; insider retains meaningful direct and indirect holdings.
The transaction code F and the filing explanation indicate this was a routine disposition to cover tax obligations arising from RSU vesting rather than a voluntary opportunistic sale. The amount disposed (123 shares) at $175.91 is modest relative to the reported direct holding of 8,338 shares. Holdings also include shares in a trust (358) and a 401(k) allocation (1,628), which suggests ongoing equity ownership alignment with company performance. This filing is informational and not materially transformative for investors.
TL;DR: Filing documents routine tax-withholding sale and confirms continued insider exposure to company stock.
The explanatory notes explicitly state the disposition was solely to cover tax withholding from RSU vesting, which supports customary corporate governance practices for equity compensation. The use of an attorney-in-fact signature is noted and appears administrative. No indication of accelerated selling, option exercises, or derivative transactions is present. From a governance perspective, the report documents compliance with Section 16 reporting requirements and preserves transparency about insider ownership levels.
La comunicazione riporta un'operazione insider effettuata da Karthik Kuppusamy, SVP Clinical Solutions presso Quest Diagnostics (DGX). In data 13/08/2025 ha effettuato una cessione di 123 azioni ordinarie di Quest Diagnostics, eseguita con codice F al prezzo di $175,91 per azione; il dichiarante precisa che la vendita 猫 stata fatta esclusivamente per coprire il prelievo fiscale su stock unit gi脿 maturate. Dopo la transazione segnalata, Kuppusamy deteneva 8.338 azioni direttamente, oltre a 358 azioni indirettamente tramite un trust e 1.628 azioni nel piano 401(k), importo fornito dall'amministratore del piano in base ai saldi correnti del conto.
El informe comunica una operaci贸n de insider realizada por Karthik Kuppusamy, SVP de Clinical Solutions en Quest Diagnostics (DGX). El 13/08/2025 tuvo una disposici贸n de 123 acciones ordinarias de Quest Diagnostics ejecutada bajo el c贸digo F a $175.91 por acci贸n; el declarante indica que la venta se realiz贸 煤nicamente para cubrir la retenci贸n fiscal sobre unidades restringidas de acciones ya consolidadas. Tras la operaci贸n reportada, Kuppusamy pose铆a 8.338 acciones en propiedad directa, adem谩s de 358 acciones indirectamente a trav茅s de un fideicomiso y 1.628 acciones en el plan 401(k), cantidad facilitada por el administrador del plan seg煤n los saldos actuales de la cuenta.
鞚� 瓿奠嫓電� Quest Diagnostics(DGX)鞚� SVP, Clinical Solutions鞚� Karthik Kuppusamy鞚� 雮措秬鞛� 瓯半灅毳� 氤搓碃頃╇媹雼�. 2025-08-13鞐� 攴鸽姅 旖旊摐 F搿� 鞁ろ枆霅� Quest Diagnostics 氤错喌欤� 123欤� 觳橂秳鞚� 欤茧嫻 $175.91鞐� 歆勴枆頄堨溂氅�, 鞁犼碃鞚胳潃 鞚� 毵り皝鞚� 鞚措 頇曥爼霅� 鞝滍暅 欤检嫕 雼渼鞚� 靹戈笀 鞗愳矞歆曥垬鞖�鞙茧毵� 鞚措（鞏挫雼り碃 氚濏様鞀惦媹雼�. 氤搓碃霅� 瓯半灅 鞚错泟 Kuppusamy電� 歆侅爲 氤挫湢 8,338欤�鞕赌 鞁犿儊鞚� 韱淀暅 臧勳爲 氤挫湢 358欤�, 攴鸽Μ瓿� 401(k) 頂岆灉鞐� 氤挫湢霅� 1,628欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 401(k) 靾橃箻電� 頂岆灉 甏�毽瀽鞐� 鞚橅暣 順勳灛 瓿勳 鞛旍暋鞚� 旮办鞙茧 鞝滉车霅橃棃鞀惦媹雼�.
Le d茅p么t signale une op茅ration d'initi茅 r茅alis茅e par Karthik Kuppusamy, SVP Clinical Solutions chez Quest Diagnostics (DGX). Le 13/08/2025, il a proc茅d茅 脿 une cession de 123 actions ordinaires de Quest Diagnostics ex茅cut茅e sous le code F au prix de 175,91 $ par action ; le d茅clarant indique que cette vente a 茅t茅 effectu茅e uniquement pour couvrir la retenue fiscale sur des unit茅s d'actions restreintes acquises. Apr猫s la transaction signal茅e, Kuppusamy d茅tenait 8 338 actions en propri茅t茅 directe, plus 358 actions indirectement via une fiducie et 1 628 actions d茅tenues dans le plan 401(k), le montant 401(k) ayant 茅t茅 fourni par l'administrateur du plan sur la base des soldes de comptes actuels.
Die Meldung berichtet 眉ber Insider-Aktivit盲ten von Karthik Kuppusamy, SVP Clinical Solutions bei Quest Diagnostics (DGX). Am 13.08.2025 ver盲u脽erte er unter dem Code F 123 Aktien der Quest Diagnostics-Stammaktien zu einem Preis von $175,91 je Aktie; der Einreicher gibt an, dass der Verkauf ausschlie脽lich zur Deckung der Steuerabz眉ge auf ausge眉bte Restricted Stock Units erfolgt sei. Nach der gemeldeten Transaktion besa脽 Kuppusamy 8.338 Aktien direkt, zus盲tzlich 358 Aktien indirekt 眉ber einen Trust und 1.628 Aktien im 401(k)-Plan, wobei der 401(k)-Betrag vom Planadministrator auf Grundlage der aktuellen Kontost盲nde angegeben wurde.
FAQ
What transaction did Karthik Kuppusamy report on Form 4 for DGX?
Why were the 123 shares disposed according to the Form 4?
How many Quest Diagnostics shares does the reporting person beneficially own after the transaction?
Does the Form 4 report any derivative transactions or option exercises?
Who signed the Form 4 on behalf of Karthik Kuppusamy?
